The lack of new antibiotics is among the most critical challenges facing medicine. The problem is particularly acute for Gram-negative bacteria. An unconventional antibiotic strategy is to target bacterial nutrition and metabolism. The metal gallium can disrupt bacterial iron metabolism because it substitutes for iron when taken up by bacteria. We investigated the antibiotic activity of gallium ex vivo, in a mouse model of airway infection, and in a phase 1 clinical trial in individuals with cystic fibrosis (CF) and chronic Pseudomonas aeruginosa airway infections. Our results show that micromolar concentrations of gallium inhibited P. aeruginosa growth in sputum samples from patients with CF. Ex vivo experiments indicated that gallium inhibited key iron-dependent bacterial enzymes and increased bacterial sensitivity to oxidants. Furthermore, gallium resistance developed slowly, its activity was synergistic with certain antibiotics, and gallium did not diminish the antibacterial activity of host macrophages. Systemic gallium treatment showed antibiotic activity in murine lung infections. In addition, systemic gallium treatment improved lung function in people with CF and chronic P. aeruginosa lung infection in a preliminary phase 1 clinical trial. These findings raise the possibility that human infections could be treated by targeting iron metabolism or other nutritional vulnerabilities of bacterial pathogens.
INTRODUCTION
In addition to treating primary infection, antibiotics provide a protective umbrella under which much of modern medicine operates. Patients undergoing surgery, invasive procedures, immune modulation, and cancer therapy all depend upon antibiotics. However, antibiotic effectiveness is threatened. Among the most pressing challenges are escalating antibiotic resistance of both hospital-and community-acquired organisms (1, 2) and the increasing prevalence of pathogens with high intrinsic resistance (3) . In addition, antibiotics work poorly against chronic infections because the bacterial growth mode at chronic infection sites produces an antibiotic-tolerant phenotype (4) . The problem is particularly acute for Gram-negative bacteria because of their low cell wall permeability and effective and redundant efflux systems (5, 6 ).
An unconventional approach to combat infection is to exploit nutritional vulnerabilities of bacteria, and bacterial iron metabolism is a prime candidate. Iron is essential for almost all pathogens because it is required in enzymes mediating DNA synthesis, electron transport, oxidative stress defense, and other key processes (7) . Moreover, free iron concentrations are extremely low in vivo (~10 −20 M) because of the insolubility of iron in aerobic environments and the multiple host defenses that sequester iron (7) . In addition, in vitro work indicates that iron metabolism may be a particular vulnerability for organisms in biofilm-like aggregates found at sites of chronic infections in people with wounds, cystic fibrosis (CF), and other conditions (8) . Despite these factors, approved therapeutics targeting bacterial iron metabolism have not yet been developed.
One potential approach uses the metal gallium as a "Trojan horse" to disrupt iron metabolism. Gallium has a nearly identical ionic radius as iron, and some bacterial uptake systems are unable to distinguish gallium from iron (9, 10) . Gallium disrupts iron-dependent processes because it cannot be reduced in physiological conditions, and iron's biological functions involve redox cycling (10) . Thus, gallium incorporation into iron-containing proteins disrupts their functioning.
Previous work by others and us found that gallium compounds had antibacterial activity against a number of human pathogens including Pseudomonas aeruginosa (11) , Francisella tulerensis (12) , Acinetobacter baumannii (13) , several mycobacterial species (14, 15) , Klebsiella pneumoniae (16, 17) , and other important pathogens (18) (19) (20) . Work with P. aeruginosa showed that gallium was effective against bacteria grown as biofilms, in stationary-phase cultures, and against multidrug-resistant CF clinical isolates (11) .
Here, we tested gallium's effectiveness as an anti-infective treatment. We measured gallium's activity in human CF sputum, performed experiments to understand gallium's mechanism of action, investigated the potential for gallium resistance, and studied gallium's combined activity with conventional antibiotics. We also tested gallium in murine infections and report the results of a Iron-limiting conditions in sputum enhance gallium's antibacterial effect To determine how iron concentrations in CF sputum affect gallium's activity, we measured gallium's antibacterial effect in CF sputum with and without iron addition. In the absence of added iron, 4.0 or 5.0 M gallium completely inhibited P. aeruginosa growth in all sputum samples we tested, and in some samples, gallium was effective at 10-fold lower concentrations ( Fig. 2A and fig. S3 ). Adding growth-stimulatory quantities of iron to sputum decreased the activity of the lowest gallium concentrations we tested; however, gallium concentrations that strongly suppressed growth in the unsupplemented condition (≤4.0 M) were still effective after FeCl 3 addition (Fig. 2B) .
Gallium inhibits some iron-containing enzymes in P. aeruginosa
We studied gallium's mechanism of action against P. aeruginosa by investigating gallium's effect on key iron-containing enzymes. The iron-dependent enzyme ribonucleotide reductase is essential for DNA synthesis, and gallium has been shown to inhibit Mycobacterium tuberculosis growth by inhibiting cellular ribonucleotide reductase activity (15) . We investigated gallium's effect in an iron-rich media in which gallium's antimicrobial activity was inhibited to reduce the chance that enzyme activity measurements were confounded by nonspecific changes associated with bacterial death.
As shown in Fig. 3A and consistent with our previous observations with M. tuberculosis (15) , gallium progressively inhibited P. aeruginosa ribonucleotide reductase activity reaching a maximum of ~40% inhibition at a gallium concentration of 20 M in this and S2). Error bars indicate SEM. *P < 0.01 versus no iron addition, Student's t test. (B and C) Effect of adding iron trichloride (FeCl 3 ) on the expression of the pyoverdine biosynthetic gene pvdA (B) and on pyoverdine production (C) by P. aeruginosa in CF sputum. Results are mean of two replicates. Error bars indicate SEM. *P < 0.01 versus no iron addition, Student's t test (also see fig. S1 for experiments with sputum from another subject). OD 600 , optical density at 600 nm; RFU, relative fluorescence units.
medium. However, further inhibition was not seen when the gallium concentration was increased (Fig. 3A) . This result raises the possibility that gallium inhibits one of the two classes of P. aeruginosa ribonucleotide reductase (24) , but not the other.
We also exposed live bacteria to gallium to investigate gallium's effect on the activity of aconitase, an iron-sulfur enzyme that catalyzes the isomerization of citrate to isocitrate in the tricarboxylic acid cycle (15) . Previous work indicated that exposure to gallium decreased M. tuberculosis aconitase activity (15) . However, we found no effect of gallium on P. aeruginosa aconitase activity, even after a 24-hour incubation with up to 60 M gallium (Fig. 3B) , which inhibited bacterial growth in this medium.
Catalase and iron-superoxide dismutase (Fe-SOD) are key bacterial antioxidant enzymes that contain iron in their active sites. Consistent with our previous results with Francisella novicida (12) , incubation of P. aeruginosa in the presence of increasing concentrations of gallium decreased P. aeruginosa catalase activity up to 70% (Fig. 3C) . However, in these assay conditions, we found no detectable inhibition of P. aeruginosa SOD activity (Fig. 3D ).
Gallium increases P. aeruginosa oxidant sensitivity
Gallium-mediated inhibition of catalase activity could increase bacterial sensitivity to oxidants, which are key effectors of epithelial and phagocyte-mediated bacterial killing (25) . To explore this possibility, we exposed P. aeruginosa to subinhibitory concentrations of gallium and measured the sensitivity of P. aeruginosa to killing by oxidants. Gallium exposure increased P. aeruginosa sensitivity to hydrogen peroxide (H 2 O 2 ) and tert-butyl hydroperoxide (tert-butyl) (Fig. 4,  A and B) . In contrast, gallium did not increase sensitivity to paraquat (PQ) or phenazine methosulfate (PMS) (Fig. 4, C and D) , which primarily generate superoxide. These findings are consistent with our data indicating that gallium inhibits P. aeruginosa catalase that catabolizes H 2 O 2 , but not SOD that converts superoxide to H 2 O 2 .
P. aeruginosa develops gallium resistance at rates comparable to successful antibiotics Most successful antibiotics inhibit multiple essential bacterial functions, and this may slow drug resistance (26) . For example, ciprofloxacin targets DNA gyrase and topoisomerase, and -lactam antibiotics target multiple penicillin-binding proteins (26) . The fact that gallium can substitute for iron in many proteins and interferes with multiple bacterial functions (see Figs. 3 and 4) led us to hypothesize that P. aeruginosa may develop resistance to gallium at low rates, similar to successful antibiotics that have multiple targets.
We compared the frequency at which P. aeruginosa develops spontaneous resistance to gallium and to the conventional antipseudomonal antibiotics colistin, ciprofloxacin, and tobramycin. Spontaneous resistance was defined as the heritable ability to grow in the presence of four times the minimal inhibitory concentration (MIC) of each agent. About 1 in 30 million P. aeruginosa cells spontaneously developed resistance to gallium (Table 1) . Spontaneous resistance to the other antibiotics tested occurred about two times more frequently (Table 1) .
We also measured the rate at which mutations arise under selection by passaging 12 replicate cultures of wild-type P. aeruginosa in gallium, aztreonam, and tobramycin for 12 days. Whereas resistance to gallium and the tested antibiotics increased significantly after passaging (P < 0.01), relative gallium resistance increased less (P < 0.01). (Fig. 5, A to C) . The relatively low rates of gallium resistance in both assays are consistent with our previous finding that except for one outlier (of 115 strains tested), the most resistant P. aeruginosa clinical isolate we tested had an inhibitory concentration only fourfold higher than the gallium-susceptible laboratory strain, PA01 (11). Transposon mutagenesis identifies few gene inactivation producing gallium resistance Recent work using transposon mutagenesis in P. aeruginosa PA14 found that inactivation of the hitA gene, which encodes a periplasmic iron +3 transporter, produced fourfold reductions in gallium sensitivity (27) . We used three approaches to determine whether additional resistanceproducing gene inactivation mutations could be identified.
First, because resistance elements may be strain-specific, we repeated transposon mutagenesis using the P. aeruginosa strain PA01, which is the reference strain most phylogenetically related to CF clinical isolates and is among the most divergent reference strain from PA14 (28, 29) . Genome saturation-scale transposon mutagenesis in PA01 (total of ~120,000 mutants screened) found no additional mutants [other than hitA, as found by (27) ] to be associated with gallium resistance (table S1) .
Second, we performed genome-saturating transposon mutagenesis in a PAO1 strain in which the hitAB genes had been deleted. This screen of ~240,000 transposon mutants found only two mutants with gallium resistance higher than the hitAB deletion strain (table S1). The transposon insertions were mapped to the open reading frame of PA5248, which has homology to an inner membrane iron permease gene (the FTR1/Fip1/EfeU family), and to the intergenic region between the pvdA and fpvI genes, both of which are involved in iron acquisition (21) . Adding transposon mutations in PA5248 or the pvdA-fpvI intergenic region to the hitAB deletion strain increased resistance by only about twofold ( fig. S4 ).
Third, we passaged 12 replicate cultures of the P. aeruginosa hitAB deletion strain in gallium for 12 days and found that whereas this strain exhibited a higher starting inhibitory concentration than wild type, prolonged passaging produced smaller relative increases in gallium resistance as compared to wild type (P < 0.0001) (Fig. 5D ). Together, this work suggests that marked gallium resistance is not likely to occur at high frequencies and that inactivation of the hitAB iron transporter is the main pathway to resistance. 
Gallium is synergistic with two anti-pseudomonal antibiotics
Gallium's unique mechanism makes its combined activity with antibiotics difficult to predict. We used three independent assays to measure the combined activity of gallium and antibiotics including the agar disc diffusion, time-kill, and checkerboard (isobologram) assays (30) . All three assays detected synergistic interactions between gallium and colistin (polymyxin E) and gallium and piperacillin/tazobactam. Synergy was indicated by convex inhibition zones between gallium and antibiotic discs in disc diffusion assays (Fig. 6, A and B) , increased bactericidal activity in time-kill assays (Fig. 6, D and E) , and concaveshaped isobolograms in checkerboard assays (Fig. 6, G and H) . In contrast, gallium was antagonistic to tobramycin's activity (Fig. 6 C, F, and I), and neither synergistic nor antagonistic interaction effects were seen with ciprofloxacin, aztreonam, or ceftazidime ( fig. S5 ). These findings could inform future clinical studies that combined gallium with conventional antibiotics.
Gallium does not inhibit the antimicrobial activity of macrophages
Gallium is used clinically to treat hypercalcemia of malignancy because it inhibits bone reabsorption by osteoclasts (10, 29) , which are myeloid cells. Macrophages (also myeloid cells) are present in chronically infected CF airways and take up gallium (31) . These facts raise concern that gallium could negatively affect macrophage function. To test this, we isolated human monocytes, differentiated them to human monocyte-derived macrophages (HMDMs), and treated the HMDMs with vehicle or gallium. We used a long exposure (24 hours) and a gallium (100 M) concentration that was ~20 to 200 times the concentration that inhibited P. aeruginosa in sputum and ~10 times the concentration detected in sputum in the clinical trial (see below) for these experiments to maximize the chances of detecting toxic effects.
Gallium treatment did not reduce HMDM viability ( fig. S6A ), but it modestly affected the expression of some genes mediating bacterial uptake and killing ( fig. S6B ). We directly tested gallium's effects on macrophage antimicrobial activity using HMDMs isolated from two healthy donors and found that continuous exposure to 100 M gallium for 24 hours did not reduce macrophage P. aeruginosa killing (fig. S6C ).
Parenteral gallium effectively treats P. aeruginosa mouse lung infections
We focused on proof-of-principle in vivo studies (in mice and humans) on systemic rather than inhaled gallium treatment because intravenous gallium nitrate [Ga(NO 3 ) 3 ] is already approved by the U.S. Food and Drug Administration for a noninfection indication (hypercalcemia of malignancy). We began by testing parenteral gallium in a mouse model of P. aeruginosa lung infections using a single dose administered 3 or 12 hours after mice were infected with P. aeruginosa. Gallium treatment increased mouse survival (P < 0.001) (Fig. 7A) and reduced lung and blood P. aeruginosa counts (P < 0.001) (Fig. 7B) .
To determine whether disrupted iron metabolism explained gallium's efficacy, we exogenously added an iron solution into mouse airways immediately before infection and found that iron addition reduced gallium's therapeutic effect (P < 0.001) (Fig. 7C) . These data show that systemic gallium is effective in a model acute lung infection (even when administered well after the bacteria) and suggest that as seen in vitro, gallium's in vivo activity results from disruption of iron-dependent processes.
A proof-of-principle phase 1 clinical trial of gallium in CF Given in vitro and in vivo preclinical data suggesting efficacy, we tested intravenous gallium administration in people with CF and chronic P. aeruginosa lung infections in a pilot phase 1b nonrandomized study (investigator-initiated: IND #104,363; ClinicalTrials.gov: NCT01093521). We enrolled 20 patients, evenly divided between genders, with a median age of 32.8 years (range, 19 to 54.2) and a mean forced expiratory volume in 1 s (FEV 1 ) of 2.24 liters (range, 1.06 to 4.59 liters) (see tables S2 and S3 for inclusion and exclusion criteria and enrollment).
The primary endpoints were safety, tolerability, and pharmacokinetics; however, we also measured efficacy endpoints including change in lung function as measured by FEV 1 and forced vital capacity (FVC) (from baseline to days 7, 14, and 28) and change in sputum P. aeruginosa density (from baseline to days 7, 14, and 28). We sequentially studied two dose regimes to enable early detection of adverse effects. Cohort 1 received a low dose, 100 mg/m 2 per day (9 subjects: 4 males and 5 females), and cohort 2 received 200 mg/m 2 per day (11 subjects: 6 males and 5 females). No serious adverse events were noted, and kidney function, electrolyte concentrations, and blood counts were all unaffected (table S4 and fig. S7 ). Steady-state plasma and sputum concentrations were achieved by 2 days (Fig. 8, A and B, and fig. S8 ). Gallium plasma and sputum area under the curve (AUC) concentrations did not change with increased dose (table S5), likely because gallium's saturable protein binding [for example, to transferrin and albumin (32)] causes unbound gallium concentrations to increase at higher doses, which, in turn, increases renal and nonrenal elimination (33) .
Plasma and sputum gallium concentrations remained detectable for prolonged periods (Fig. 8, A and B, and fig. S8 ). The average plasma and sputum elimination half-life (T 1/2 ) of gallium exceeded 100 and 220 hours, respectively, in both cohorts (table S5) . Sputum concentration increased after the end of the infusion, increasing, on average, more than twofold by day 14, and only decreased by ~50% on day 28 ( Fig. 8B and table S5 ). These findings suggest that a depot compartment exists, which could explain the prolonged improvement in lung function we observed (see below). Analysis of pooled data (from cohorts 1 and 2) showed statistically significant increases in lung function (both FEV 1 and FVC) 14 and 28 days after a single infusion of gallium (P < 0.005) (Fig. 8C , Table 2, and table S6) . Data from the individual cohorts are shown in Fig. 8 (D and E) and table S6. When defined by the proportion of subjects achieving a 5% FEV 1 improvement, 73 and 45% of cohort 2 were responders at days 14 and 28, respectively, compared to 22 and 44% of cohort 1 at days 14 and 28, respectively (P values in table S6). However, we found no correlation between lung function response and peak or AUC sputum gallium concentrations (table S7) . Mean and median P. aeruginosa density declined by 5.5 million and 1.8 million CFU/g between days 0 and 14 and by 29.8 million and 3.9 million CFU/g between days 0 and 28 (Table 2 ), but these changes were not statistically significant.
DISCUSSION
Whereas the idea of disrupting bacterial nutrition as an antimicrobial strategy was raised by Louis Pasteur in the 1800s (34) , therapeutic approaches that exploit bacterial nutrient vulnerabilities have been difficult to develop. Our results indicate that gallium can act as a chemical mimic to disrupt P. aeruginosa iron metabolism, that gallium resistance develops at low rates, and that gallium's antibacterial activity may be enhanced by some conventional antibiotics. Furthermore, our preliminary proof-of-concept clinical study raises the possibility that gallium may be a safe and effective treatment for human infections.
Gallium's ability to generally substitute for iron suggests that gallium could disrupt several aspects of bacterial physiology, and our experiments and previous gene expression analysis (11) support this idea. Activity assays indicated that gallium inhibits enzymes mediating bacterial DNA synthesis and antioxidant defense and sensitized bacteria to killing by peroxides. Previous gene expression assays indicated that gallium disrupts carbon utilization and protein synthesis and represses key iron uptake systems including those mediating heme/hemoglobin and pyoverdine uptake (21) . The finding that gallium suppresses iron uptake and our data indicating that day, respectively) combined (see fig. S8 for data from each cohort separated). Mean change in lung function (as measured by FEV 1 in mls) by study day for both cohorts pooled together (C) and cohorts 1 (D) and 2 (E) separately (100 mg/ m 2 per day and 200 mg/m 2 per day, respectively). Bars represent the 95% confidence intervals (CIs). P values are indicated on graphs. Inferential analyses of the change from baseline tested the null hypothesis that the change is equal to zero using paired t tests with normally distributed data with 95% CIs.
low iron concentrations enhances gallium's activity raises the possibility that gallium effects on bacterial physiological might potentiate its own activity. The multiplicity of gallium effects could provide advantages of target redundancy, which could explain our finding that gallium resistance emerged at low rates, comparable to antibiotics that target multiple processes. Also promising, the bacterial functions that we identified as being gallium-inhibited are not targeted by antibiotics in clinical use. This could explain our previous finding that multidrug-resistant P. aeruginosa isolates showed similar degree of gallium sensitivity as antibiotic-sensitive laboratory strains (11) .
The magnitude of gallium-associated lung function improvement we identified in the pilot clinical trial is similar to that produced by approved antibiotics in CF. For example, 14-day-long treatment using a combination of two intravenous anti-pseudomonal antibiotics chosen on the basis of the antimicrobial susceptibility of subject's P. aeruginosa strains improved FEV 1 by ~7%, when measured immediately (12 to 48 hours) after the last antibiotic dose (35) . Likewise, high doses of tobramycin and aztreonam administered by inhalation twice or three times daily for month-long courses improved FEV 1 by 2.7 to 10.3%. The lung function improvements produced by conventional antibiotics in these studies waned 2 to 4 weeks after the drug was stopped (36-39), whereas gallium-associated changes persisted to the last time point we measured (day 28).
Although the results were encouraging, our study had several limitations. First, the sputum activity, mechanism of action, resistance and synergy, and animal experiments were performed with the P. aeruginosa strain, PA01, and it is possible that different strains could give different results. This limitation is mitigated somewhat because PA01 is the reference strain most phylogenetically related to CF isolates (28) . Furthermore, our previous work testing 120 CF clinical P. aeruginosa isolates (including multidrug-resistant strains) (11) found these generally gallium-susceptible. In addition, the results of our phase 1 human trial suggest that gallium activity is not dependent on the presence of a particular P. aeruginosa strain because CF subjects are generally infected by different environmental strains.
Second, although we measured resistance using three independent assays (that is, spontaneous mutants, passaging under selection, and transposon mutagenesis), combined action with antibiotics using three independent assays (disc diffusion, time-kill, and checkerboard), and found concordant results, it is possible that these do not reflect in vivo activity. Third, although gallium treatment produced statistically significant improvements in lung function (despite the small numbers of subjects studied), declines in P. aeruginosa burden did not reach significance. The absence of statistically significant reductions in P. aeruginosa counts could be due to the variability of enumerating bacterial counts in sputum, or if gallium's beneficial effect on lung function was due to its previously described anti-biofilm (11) or anti-inflammatory (40-43) effects or activity against other bacteria that may coinhabit CF airways.
Fourth, the clinical study was limited to subjects with mild disease, and gallium's efficacy could be reduced in severe CF because lung function and sputum total iron and iron +2 concentrations may be inversely correlated (44) . However, gallium's efficacy was maintained even when growth-stimulating concentrations of iron are added to CF sputum, higher molar ratios of iron (than gallium) are required to restore growth of gallium-treated bacteria (11) , and gallium inhibits P. aeruginosa iron uptake (11) . It is unclear whether these factors could mitigate the effects of increased in vivo iron availability or increase gallium's efficacy.
Finally, the clinical trial was small, unblinded, and did not have a placebo control. Thus, the promising safety and efficacy results need to be confirmed in a larger placebo-controlled study. It will also be important to study the safety of repeated administration, investigate combined use with antibiotics in humans, and determine whether oral or inhaled treatment is feasible.
The public health crisis of antibiotic resistance has spurred studies of nonconventional antimicrobial approaches. Our proof-ofprinciple work with P. aeruginosa and the fact that gallium has broad-spectrum activity against many extracellular and intracellular pathogens raise the possibility that gallium or other iron-disrupting strategies may be useful in infections caused by a range of resistant organisms. This work also suggests a renewed focus on targeting bacterial nutrition and metabolism to treat infectious diseases. 
METHODS

Study design
The objectives of this work were to test gallium as a potential antibacterial treatment for people with CF and chronic P. aeruginosa lung infections. We used in vitro experiments to investigate Ga(NO 3 ) 3 mechanism of action, gallium resistance, the combined activity of gallium with antibiotics, and gallium's effect on macrophage activity. We also tested gallium in mice infected with P. aeruginosa and in people with CF and chronic P. aeruginosa lung infections in a nonrandomized phase 1 clinical trial (see below).
Ex vivo assays
Sputum was collected from CF patients and used for growth studies (45) using strains PAO1 and PAO1-pvdA-gfp (46) . Basal medium 2 (BM2) medium was used for oxidant sensitivity, time-kill, checkerboard, spontaneous and selected mutation rate assays, and selection of transposon mutants. The highest drug concentrations that permitted growth before passaging (in the selected resistance assays) were 1 g/ml for tobramycin and aztreonam, 64 μg/ml gallium for wild-type P. aeruginosa, and 128 μg/ml gallium for hitAB P. aeruginosa. LB agar plates were used in disc diffusion assays. Enzyme activity assays were preformed in 10% tryptic soy broth medium. Transposon mutagenesis was performed using the mini-Tn5-pro delivered on pUT from Escherichia coli S17-1 (see the Supplementary Materials for additional information).
Mouse infections
All experiments were approved in advance by the University of Washington Animal Care and Use Committee and used 8-to 12-week-old C57Bl/6 pathogen-free mice (The Jackson Laboratory). Animals were euthanized if they became moribund, distressed, or unable to eat or drink (see the Supplementary Materials for additional information).
Human studies
Macrophage studies were approved by the University of Chicago Institutional Biosafety Committee, and the trial of intravenous Ga(NO 3 ) 3 (ClinicalTrials.gov: NCT01093521) was performed under IND #104,363, with Institutional Review Board (IRB) approval from all three study sites (UW IRB 35876, UI IRB-01 201002774, and JHU IRB5 NA_00044996).
Subjects were included in the phase 1b clinical trial if they were between 18 and 55 years of age, had a confirmed diagnosis of CF with chronic P. aeruginosa lung infection, and did not have severe lung dysfunction (FEV 1 > 30% of predicted). In addition, subjects were required to be without clinically significant renal or liver disease and not be experiencing acute disease flares (see tables S3 and S4 for inclusion and exclusion criteria and enrollment).
Gallium can cause nephrotoxicity after large intravenous boluses because rapid infusion saturates the binding capacity of galliumbinding proteins (10, 33) . CF patients frequently receive nephrotoxic drugs, so we administered Ga(NO 3 ) 3 by slow continuous intravenous infusion over 5 days, which has been shown to markedly reduce nephrotoxicity as compared to bolus infusion (10) . Subjects were also instructed to consume 2 liters of fluid above their normal intake during the infusion period. Subjects received a single 5-day infusion of Ga(NO 3 ) 3 (two dosing cohorts noted above). Cohort 2 did not commence until review of cohort 1 safety data by the Data Safety Monitoring Committee.
Statistical analysis
For the laboratory-based studies, we present descriptive statistics including SD and SE. For between-group comparisons, we used Student's t test. For non-normally distributed variables, MannWhitney U test was performed. For the clinical trial, inferential analyses of the lung function changes tested the null hypothesis that the change was equal to zero using paired t tests with normally distributed data with 95% CIs and Wilcoxon signed-rank tests with non-normally distributed data with IQR. Table 2 notes both mean and median values with SD and IQR. Lung function is measured by both FEV 1 and FVC in liters. Quantitative sputum P. aeruginosa concentrations are measured in million CFU/gm. We report the proportion of patients with a 5% improvement in FEV 1 because this is considered clinically significant in CF (36) (37) (38) (39) . The change in proportion is noted by the 95% CIs of that change. Inferential analyses of the change from baseline tested the null hypothesis that the change is equal to zero using paired t tests with normally distributed data with 95% CIs. Wilcoxon signed-rank tests were used with non-normally distributed data with IQR.
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